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Abstract
Background and Purpose—Despite the rapidly increasing global burden of ischemic stroke, 
no therapeutic options for neuroprotection against stroke currently exist. Recent studies have 
shown that autophagy plays a key role in ischemic neuronal death and treatments that target 
autophagy may represent a novel strategy in neuroprotection. We investigated whether autophagy 
is regulated by carnosine, an endogenous pleiotropic dipeptide which has robust neuroprotective 
activity against ischemic brain damage.
Methods—We examined the effect of carnosine on mitochondrial dysfunction and autophagic 
processes in rat focal ischemia and in neuronal cultures.
Results—Autophagic pathways such as reduction of phosphorylated mTOR/p70S6K and the 
conversion of LC3-I to LC3-II were enhanced in the ischemic brain. However, treatment with 
carnosine significantly attenuated autophagic signaling in the ischemic brain, with improvement of 
brain mitochondrial function and mitophagy signaling. The protective effect of carnosine against 
autophagy was also confirmed in primary cortical neurons.
Conclusion—Taken together, our data suggest that the neuroprotective effect of carnosine is at 
least partially mediated by mitochondrial protection, and attenuation of deleterious autophagic 
processes. Our findings shed new light on the mechanistic pathways that this exciting 
neuroprotective agent influences.
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Introduction
Despite the high prevalence and the increasing global burden of ischemic stroke, there are 
no approved neuroprotective agents in clinical use. The only approved therapy is 
thrombolysis with tissue plasminogen activator (tPA), which has a narrow therapeutic 
window and hemorrhagic side effects that limit clinical use. There have been extensive 
efforts to develop novel therapeutic candidates for ischemic stroke.1,2 However, numerous 
promising candidates have failed in clinical trials due to a number of factors which include 
poor preclinical study design, illogical clinical translation of preclinical data, poor efficacy 
and serious side effects.3,4 Moreover, understanding the precise mechanisms through which 
candidate agents exert their protective effects is an important and critical part of therapy 
development. Agents that influence multiple deleterious pathways are more likely to be 
efficacious clinically.5,6
There is increasing evidence that autophagy, a highly regulated cellular process that involves 
degradation of cellular proteins and organelles, can contribute to neuronal death during brain 
ischemia. Enhancement of autophagic processes was observed in brain after hypoxic-
ischemia,7 and the occurrence of autophagy measured by conversion of LC3-I to LC3-II 
during brain ischemia has been confirmed by in vivo imaging.8 Although controversy exists 
whether autophagy contributes to cell death or cell survival,9-11 recent observations using 
inhibitors or modulators of autophagy revealed that autophagy mediates neuronal cell death 
during ischemia.12,13 Wen et al14 observed autophagy in focal cerebral ischemia, and 
demonstrated that treatment with inhibitors of autophagy significantly reduced brain 
damage. Data also exist showing that neuronal death during ischemia is mediated by 
oxidative stress generated from autophagosomes and mitochondria that are participating in 
the autophagic process.15
Activation of autophagic pathways is associated with perturbations in mitochondrial 
function.16 Mitochondrial damage is known to result in activation of mitophagy, a specific 
type of autophagy that eliminates dysfunctional mitochondria,17,18 under normal as well as 
pathological conditions including cerebral ischemia.19 Despite the increasing attention on 
autophagy as a novel target for stroke therapy development, studies on agents that modulate 
autophagy and that could be used clinically are still limited.
Carnosine, an endogenous dipeptide, is a pleotropic agent that exhibits diverse activities 
including anti-oxidant, anti-matrix metalloproteinase, heavy metal chelating and anti-
excitotoxic properties.20,21 We recently showed that carnosine robustly reduced brain 
damage after ischemic stroke.22-25 Post-treatment with carnosine protected against 
histological brain damage both in permanent- and transient-ischemic rat models with a wide 
clinically relevant therapeutic window of 9 hr and 6 hr, respectively, along with 
improvements in functional outcomes.23 Carnosine did not exhibit any side effects or organ 
toxicity.23,25 Along with our observation, others have also reported the robust 
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neuroprotective activity of carnosine.26-28 However, it is not known whether carnosine can 
influence autophagy in the ischemic brain.
In the current study, we have investigated whether carnosine has the ability to modulate 
autophagic processes in the ischemic brain using both in vitro and in vivo approaches. We 
extended our studies to mitochondria and showed that carnosine has a significant and 
profound effect on autophagy and associated mitochondrial perturbations that occur during 
ischemia. Our findings support the pleiotropic multimodal action of carnosine and provide, 
for the first time, proof of its influence on autophagy.
Materials and Methods
More details are provided in the online supplemental material.
Animals
All animal experiments were conducted using adult male Sprague-Dawley rats weighing 250 
to 300 g (Harlan, Koatech, Korea) and performed in accordance with the NIH Policy and 
Animal Welfare Act under the approval by Institutional Animal Care and Use Committee 
(IACUC) at Hanyang University.
Blinding and Randomization
Treatment groups were allocated in a randomized fashion. Investigators were blind to the 
allocation of treatment during surgeries and outcome evaluations.
Treatments
Carnosine was obtained from Sigma and dissolved in saline. Carnosine (1,000 mg/kg) was 
administered into the lateral tail vein at 6 hr after ischemic onset both in permanent and 
transient models. The choice of this dose and time window is based on previous dose finding 
studies.22-25
Ischemic stroke in rats
Permanent or transient focal cerebral ischemia was induced by intraluminal middle cerebral 
artery occlusion (MCAO).23 Ischemia was initiated by a silicone-coated 4-0 monofilament 
nylon suture (Doccol Co.) as described previously.23,29
Calculation of infarct volume
At 24 hr after onset of ischemia, rats were euthanized by isoflurane overdose, and the 
isolated brains were cut into 2 mm sections. The infarct volume for each section was 
calculated by 2% triphenyltetrazolium chloride (TTC).30
Assessment of neurological function
Deficit in neurological function was evaluated by behavioral tests including the adhesive 
tape removal test and a Rota Rod test, at 24 hr after tMCAO (6 hr ischemia).23,31 All rats 
were trained to the tests for 5 consecutive days before focal ischemia.
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Brain homogenization and mitochondria isolation
Brain samples between bregma levels +2 and -4 mm, which include ischemic core and 
penumbra, were rapidly isolated at 24 hrs after MCAO, and brain homogenates were 
obtained by homogenization in isolation buffer. Brain mitochondria was further isolated 
using Percoll gradient centrifugation.32
Western Blot of brain homogenate or isolated brain mitochondria
Processed brain homogenates or brain mitochondria were examined in western blot using 
Tris-HCl SDS-PAGE.23,32 Detailed information on primary antibodies is described in the 
online supplemental material.
Complex I activity
Complex I activity in isolated brain mitochondria was measured using colorimetric method 
as previously described with 2,6 dichloroindophenol (DCIP).33
In vitro culture of primary cortical neurons
Primary cortical neuronal cultures were established as described previously.22 Neuronal 
cultures were maintained in a CO2 incubator at 37°C, and used between days in vitro (DIV) 
7 and 11.
NMDA-induced excitotoxicity
Ischemic neuronal damage was examined by N-methyl-daspartate (NMDA)-induced 
excitotoxicity.34 NMDA-induced cytotoxicity was measured at 24 hr after NMDA exposure 
by leakage of lactate dehydrogenase (LDH). Alterations in cellular proteins were assessed 
by western blot as described earlier, with cell lysates extracted from neuronal cells using 
RIPA buffer (Thermo Scientific). To examine carnosine protection, cells were pretreated 
with carnosine for 30 min prior to NMDA stimulation.
Statistics
We calculated the means and standard errors of means (SEM) for all treatment groups. 
Differences in values were analyzed using Student t-test or analysis of variance (ANOVA), 
as appropriate, using SPSS software (Chicago, IL). Multiple comparisons were made using 
one-way ANOVA followed by Tukey test. Two-tailed Student’ s t-test analysis was used for 
comparing values between two groups. In all cases, a p value of < 0.05 was considered 
significant.
Results
Carnosine protects the ischemic brain in focal stroke
First, we examined the neuroprotective effect of carnosine in rat focal ischemia. All 
physiological variables including body temperature and cerebral blood flow (CBF) were 
maintained in the reference range. Induction of focal ischemia was attained by middle 
cerebral artery occlusion (MCAO) and verified by monitoring of CBF. Post-treatment with 
carnosine (1000 mg/kg) at 6 hr significantly reduced brain infarct volume (Fig. 1A), 
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measured by TTC-staining. Similarly, we found that carnosine improved functional 
outcomes following 6 hr transient MCAO, using a variety of tests which included the 
latency for removal of adhesive tape placed on forelimbs and the latencies to fall off from 
the accelerating Rota Rod, respectively.23,31 (Fig. 1B and 1C).
Carnosine reduced autophagy in brain homogenates
To investigate whether autophagic processes are involved in carnosine mediated protection, 
we examined the extent of conversion of LC3-I to LC3-II, an important marker of autophagy 
that is responsible for formation of autophagosome.35 A significant increase in LC3-II 
formation was observed in the ipsilateral hemisphere following ischemia. However, this 
increase in LC3-II formation was attenuated by treatment with carnosine (Fig. 2A). It is also 
well established that inhibition of the mTOR pathway plays a key role in autophagy.36 To 
investigate the effect of carnosine on the autophagic signaling pathway, we measured the 
levels of phospho-mTOR (p-mTOR) and phospho-p70S6K (p-p70S6K), a representative 
downstream target of mTOR,37 in brain homogenates after ischemia. Carnosine did not 
affect the basal activity of mTOR; similar levels of p-mTOR were observed in hemispheres 
contralateral to the ischemia in both saline- and carnosine-treated rats (Figure 2B). Ischemia 
inhibited the phosphorylated levels of mTOR, but this inhibition was blocked by carnosine. 
Similarly, reductions in the levels of p-p70S6K in ischemic brain were also reversed by 
carnosine (Fig. 2B). Taken together, these findings support the modulating role of carnosine 
on autophagy in the ischemic brain. While mTOR-autophagy pathways were significantly 
influenced by ischemia and reversed by carnosine, the level of phosphorylated ERK 1/2 was 
not changed either by ischemia or carnosine treatment (Fig. 2B), showing that the 
modulation of autophagic proteins by carnosine is not a non-specific epi-phenomenon.
Carnosine attenuates ischemic injury to mitochondria
We have previously reported that carnosine reversed the impairment of mitochondrial 
permeability transition in primary neurons and astrocytes. Since it is well established that 
mitochondrial dysfunction contributes to autophagy induction,16,18 we examined whether 
carnosine protected against mitochondrial damage and mitophagy. Ischemia resulted in 
decreased activity of complex I in isolated brain mitochondria suggesting impairment in 
mitochondrial respiratory function. Ischemic mitochondrial dysfunction was significantly 
reversed in mitochondria isolated from carnosine-treated rats (Fig. 3A). To determine if 
there is a link between mitochondrial dysfunction and autophagy, we examined the levels of 
p-Drp1 and Parkin which play key roles in mitochondrial fragmentation and mitophagy 
during cell death, respectively.38-40 The mitochondrial levels of p-Drp1 and Parkin were 
significantly increased by ischemia, but the increase of p-Drp1 and Parkin were attenuated 
by carnosine treatment (Fig. 3B).
While the levels of p-Drp1 and Parkin were increased by ischemia, the levels of cytochrome 
C and apoptosis-inducing factor (AIF) were significantly decreased in brain mitochondria 
following ischemic insult. Since cytochrome C and AIF are released from mitochondria to 
the cytosol during mitochondrial damage,32,41 these results were consistent with 
mitochondrial dysfunction. Carnosine potently inhibited the release of AIF and cytochrome 
C, demonstrating its protective activity on mitochondrial damage (Fig. 3B).
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Carnosine protects against neuronal autophagy in culture
Primary cortical neurons were transiently exposed to toxic levels NMDA, and cytotoxicity 
and autophagic signaling pathways were examined. As shown in Figure 4A, NMDA induced 
significant cytotoxicity in primary cortical neurons, and NMDA-cytotoxicity was reduced by 
carnosine treatment. Interestingly, autophagic signaling pathways including LC3-II 
formation and mTOR de-phosphorylation were significantly enhanced by NMDA exposure, 
and carnosine reversed these changes (Fig. 4B), confirming the protective effect of 
carnosine against ischemia-induced neuronal autophagy.
Discussion
Stroke involves a cascade activation of multiple deleterious pathways,2,42,43 and therefore a 
drug candidate that specifically modulates a single pathway is not likely to show clinical 
efficacy against ischemic brain damage. Many therapeutic candidates including 
neuroprotectants which had strong protective activity pre-clinically have failed in clinical 
trials.1,4 One major reason for this is that past strategies have focused on targeting one 
pathway. We have shown that carnosine is an exciting candidate for development as a stroke 
therapy.23,25 It is safe and efficacious with a large clinically relevant therapeutic time 
window. Moreover, it is a pleiotropic agent that favorably modulates several deleterious 
pathways that contribute to cell injury and cell death during and after ischemia.21,44 We 
show here, using in vitro and in vivo approaches that carnosine has a profound and 
significant effect on autophagy, a recently identified noxious pathway in ischemic stroke. 
We believe that the current study underlines the translational importance of carnosine as a 
therapeutic candidate against ischemic stroke where multiple deleterious pathways aggravate 
neuronal damage.
Autophagy is the cellular process that mediates degradation of cellular proteins and 
organelles and maintains homeostasis.45 Despite its essential role in normal cellular 
physiology, excessive activation of autophagic pathways is also reported to be highly 
associated with many disease states including brain damage.46,47 Autophagic cell death has 
been referred to as type II cell death, which is one of the major types of cell death along with 
apoptotic (type I) and necrotic (type III) cell death.48,49 While necrotic and apoptotic cell 
deaths have long been considered as the main pathological events in ischemic stroke,50,51 
autophagy has been recently recognized as a possible deleterious event also. Activation of 
autophagic signaling was observed in ischemic brain,52 mediating ischemic neuronal 
death.10 Notably, autophagic cell death was found to be the most important contributing 
pathway in neonatal cerebral ischemia relative to apoptosis and necrosis.53 Autophagy-
inhibitors such as 3-MA significantly reverse ischemic brain damage14 and inhibition of 
autophagy was suggested to be the main mechanism of ischemic post-conditioning 
neuroprotection.54 Conversely, it has also been reported that autophagy may play a dual role 
in neuronal survival and death during ischemia,10 and further studies on the exact molecular 
targets which switch beneficial autophagy to detrimental autophagy would give valuable 
insights for development of treatments that modulate autophagy.
The role of mitochondrial dysfunction has been proposed as a contributor to autophagy.16 
We and others have previously shown that ischemic insults to the brain induced 
Baek et al. Page 6
Stroke. Author manuscript; available in PMC 2015 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
mitochondrial permeability transition (MPT) resulting in damage to mitochondrial function 
in neurons.23,41 Onset of mitochondrial dysfunction is closely linked to initiation of 
autophagy in I/R injured myocytes,46 in rat hepatocytes,55 and in neurons.15 Damaged 
mitochondria releases cytochrome C (cyt C), AIF, and reactive oxygen species,17 which 
promote mitophagy, a form of autophagy that is involved in the removal of dysfunctional 
mitochondria. Recent data suggests that Parkin, an ubiquitin ligase that mediates 
mitophagy,40 is recruited to the damaged mitochondria.36,56 In this report, we observed the 
increased recruitment of Parkin to the mitochondria, and loss of AIF and cyt C from 
mitochondria in ischemic brain, which were significantly attenuated by carnosine, 
demonstrating its protective effect against mitophagy and ultimately autophagic neuronal 
death. Similarly, Mehta et al57 showed that selenium conserved mitochondrial function and 
stimulated mitochondria biogenesis, along with reduced autophagy in glutamate-induced 
neuronal toxicity.
Interest in the development of carnosine as an endogenous pleiotropic molecule for 
therapeutic use clinically has been increasing.20,44,58-60 Here we focused on the potential of 
carnosine against ischemic stroke. Several previous reports showed that carnosine also had 
beneficial activities in neurodegenerative diseases including Alzheimer diseases,61 and 
dementia.62 Of note, dysregulation of autophagic processes have been recently recognized to 
contribute to the progress of these neurodegenerative diseases.63,64 Further elucidation of 
carnosine's effects on autophagy in these neurodegenerative diseases is needed.
In summary, we have demonstrated that carnosine inhibits ischemia-induced autophagy and 
mitochondrial damage. This novel action of carnosine adds to the other body of compelling 
data that supports the development of carnosine as a therapeutic agent against ischemic 
stroke.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Protective effect of carnosine against brain damage during ischemic stroke
Ischemic stroke was achieved by middle cerebral artery occlusion (MCAO) in rats. (A) 
Carnosine (1000 mg/kg) was administered 6 hr after onset of ischemia. Infarct volume was 
determined by 2,3,5-triphenyltetrazolium chloride staining at 24 hr after MCAO. The 
representative photos are shown. N=13-15. *p<0.05 vs. saline-treated rats. (B and C) 
Carnosine (1000 mg/kg) was administered to rats at 6 hr after ischemic onset during 
transient MCAO (6 hr ischemia/18 hr reperfusion). Behavioral tests were performed at 24 hr 
before and after ischemia. (B) Somatosensory deficit was determined using the Adhesive 
Tape tests, where required time to remove adhesives on fore limbs were measured. (C) In 
the RotaRod test, motor-ambultatory function was determined. Latencies to fall off from the 
rotarod with accelerated speeds were measured. B: N=13-15, C: N=15-16. **p<0.01, 
#p<0.05 vs. the corresponding group. Data were expressed as mean ± SEM and analyzed by 
Student's t-test.
Baek et al. Page 11
Stroke. Author manuscript; available in PMC 2015 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Inhibitory effect of carnosine on autophagy in ischemic brain
Brain homogenates were isolated from contralateral (Contra) or ipsilateral (Ipsi) 
hemispheres from saline- or carnosine (1000 mg/kg; 6 hr post treatment)-administered rats 
following pMCAO. (A) The extent of autophagy was examined using the conversion of 
LC3-II from LC3-I. (B) Autophagic signaling was examined by phosphorylation of mTOR, 
p70S6K and ERK. The representative bands are shown. Relative density of each band was 
analyzed by ImageJ. N=4. *p<0.05, **p<0.01 vs. contralateral hemisphere from saline-
treated rats. #p<0.05 vs. ipsilateral hemisphere from saline-treated rats. Data were expressed 
as mean ± SEM and analyzed by Student's t-test.
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Figure 3. Protective effect of carnosine on mitochondrial damage in ischemic brain
Brain mitochondria were isolated from contralateral (Contra) or ipsilateral (Ipsi) 
hemispheres from saline- or carnosine (1000 mg/kg; 6 hr post treatment)-administered rats 
following pMCAO. (A) Complex I activity was measured using colorimetric method. (B) 
The extent of mitochondrial fragmentation and mitophagy was examined using the level of 
p-Drp 1 and Parkin. Mitochondrial levels of apoptosis inducing factor (AIF) and cytochrome 
C were measured. Relative density of each band was analyzed by ImageJ. N=4. *p<0.05, 
**p<0.01 vs. contralateral hemisphere from saline-treated rats. #p<0.05 vs. ipsilateral 
hemisphere from saline-treated rats. Data were expressed as mean ± SEM and analyzed by 
Student's t-test.
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Figure 4. Inhibitory effect of carnosine on neuronal autophagy following NMDA stimulation
Primary cortical neurons were pre-treated with carnosine 30 min prior to exposure to 
NMDA (N-methyl-d-aspartate; 25 μM). (A) Neuronal cell death was determined by extent 
of lactate dehydrogenase leakage at 24 hr after NMDA stimulation. N=5. (B and C) The 
conversion of LC3-II from LC3-I (B) and the phosphorylation of mTOR (C) in NMDA (25 
μM)-stimulated primary neurons with or without carnosine (100 μM) pretreatment. The 
representative bands are shown. Relative density of each band was analyzed by ImageJ. 
N=3. *p<0.05, **p<0.01 vs. control group. #p<0.05 vs. NMDA-treated group. Data were 
expressed as mean ± SEM and analyzed by one way ANOVA followed by Tukey test (A) or 
by Student's t-test (B and C).
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